(HealthDay)—Chronic immune-related adverse effects after adjuvant treatment with anti-programmed cell death 1 (anti-PD-1) immunotherapies for melanoma are more common than previously thought, according to a study published online March 25 in JAMA Oncology. J. Randall Patrinely Jr., from Vanderbilt University…
Read More
Long-term survival rates for immunotherapies could be misinterpreted
Immune checkpoint inhibitors have transformed cancer care to the point where the popular Cox proportional-hazards model provides misleading estimates of the treatment effect, according to a new study published April 15 in JAMA Oncology. The study, “Development and Evaluation of…
Read More
2 immunotherapies merged into single, more effective treatment
Some of the most promising advances in cancer treatment have centered on immunotherapies that rev up a patient’s immune system to attack cancer. But immunotherapies don’t work in all patients, and researchers have been searching for ways to increase their…
Read More